Apixaban

Direct oral anticoagulants showed greater efficacy and cost-effectiveness than low-molecular-weight heparin for treatment of cancer-associated thrombosis, according to data published in Annals of Internal Medicine.

Data suggest that apixaban, a direct oral anticoagulant, may be preferable to other drugs in its category as it was associated with a lower risk for GI bleeding compared with its counterparts.

Compared with other direct oral anticoagulants, apixaban was associated with lower rates of gastrointestinal bleeding but similar rates of ischemic stroke and all-cause mortality among adults with atrial fibrillation, data show.

Apixaban dose reduction to 2.5 mg twice daily appeared safe after 6 months of full-dose treatment for venous thromboembolism among patients with cancer, according to a study published in Journal of Thrombosis and Haemostasis.

Label-concordant dosing may benefit patients on dialysis with nonvalvular atrial fibrillation more than below-label dosing, according to data published in the American Journal of Kidney Diseases.

WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor asundexian was associated with lower bleeding rates compared with apixaban, according to the results of the PACIFIC-AF trial.

Prescriptions dispensed for apixaban beyond 90 days after hospitalization resulted in a lower rate of hospitalization for recurrent venous thromboembolism compared with warfarin beyond 90 days, according to study results published in JAMA.

Anticoagulation with rivaroxaban for patients with atrial fibrillation aged 65 years or more was associated with greater risk for major ischemic and hemorrhagic events compared with apixaban, according to data published in JAMA.

A study assessing anticoagulant use in patients on hemodialysis who were diagnosed with atrial fibrillation revealed 81.5% did not initiate treatment with any anticoagulant within 30 days of being diagnosed.

Apixaban (Eliquis, Bristol Myers Squibb/Pfizer) or standard antithrombotic treatment after transcatheter aortic valve replacement.